CAMBRIDGE, Mass. – September 29th, 2023 – HiFiBiO Therapeutics, a clinical-stage global biotech company focusing on improving patient lives with single-cell precision, today announced the appointment of Alexandre Grassin, as the Vice President of Finance to oversee the company’s finance activities, reporting to HiFiBiO’s Founder, Chairperson, and CEO, Dr. Liang Schweizer.
“I’m delighted to have a seasoned financial leader like Alex on board,” remarked Dr. Schweizer. “With over 20 years of experience in global financial management, business planning, and operational excellence, Alex will be a valuable addition to the leadership team.”
“HiFiBiO Therapeutics’ rapid advancement of novel immunotherapies into the clinic and the unique Drug Intelligence Science (DIS®) platform greatly impressed me,” commented Mr. Grassin, “I am excited to join such an enthusiastic and dedicated team of professionals working to deliver innovative therapeutics to patients.”
Prior to joining HiFiBiO Therapeutics, Mr. Grassin served as Consulting CFO at Danforth Advisors and as Chief Financial Officer for Aleva Neurotherapeutics where he supported the transition of the company from R&D to commercialization. Prior to Aleva, Mr. Grassin served as Chief Financial Officer at Genkyotex, a Swiss biotech company listed on Euronext Paris and Brussels, managing all finance and administrative activities of three entities in France and Switzerland. Mr. Grassin played a key role in the Reverse Takeover process through which Genkyotex became public in 2017 and in the strategic merger with Calliditas Therapeutics in 2020/2021. Previously, Mr. Grassin served in various senior financial roles at Alexion Pharmaceuticals and Novartis and worked as an auditor at KPMG.
About HiFiBiO Therapeutics
HiFiBiO Therapeutics is a clinical-stage global biotech pioneering a unique high-resolution translational platform (DIS®, Drug Intelligence Science) to enhance the probability of success for immunotherapies. DIS® combines unique single-cell capabilities with AI/ML approaches using patient samples to discover novel targets, effective antibody drugs, and predictive biomarkers. With DIS®, HiFiBiO gains an unprecedented understanding of immune modulation in human diseases which drives a robust clinical pipeline of transformative immunotherapies. Additionally, HiFiBiO has partnered with major multinational pharmaceutical and biotech companies applying its innovative DIS® platform and has been recognized as one of 2023’s Fierce 15 biotech companies. Additional information can be found at www.Hifibio.com.
HiFiBiO® and DIS® are trademarks of HiFiBiO and its affiliates.